One dose of Zydus Cadila’s corona drug Virafin will cost Rs 11995, know what is the company’s claim
31 Views
Share
3 Min Read
SHARE
Oxygen support to the patient decreases by taking this medicine, was effective in clinical trials
During the Corona transition period, the medical world has given its full strength to find a cure for the disease. Many companies have made vaccines to get rid of people from the corona virus and continuous experiments are also going on. Vaccines of various companies have also started giving people around the world. Covaccine and Covishield are being used in India. While the world is dependent on these vaccines to protect against the corona virus, expensive drugs like remdesivir and other steroids have been seen and heard to be used to treat those who have been hit by corona.
Pharmaceutical companies are also looking for drugs in addition to vaccines to treat corona and reduce the effect of the disease. India’s leading pharmaceutical company Zydus Cadila is also one of these, one of whose drug Virafin has been granted emergency use approval in India in the past. One of CNBC TV-18 Report According to this, the company has started dispatching this medicine of Zydus Cadila and the company has fixed the price of this medicine at Rs 11995 per dose. Summarily, the price of this medicine appears to be very high, but it has been claimed by the company that by taking this single dose medicine, the need of oxygen support of the corona patient is greatly reduced.
According to the report, if Virafin is given to the patient at an early stage after being Kovid positive, then the viral load of the patient is reduced and it helps a lot in fighting the merge. The company claims that it has shown good effect on patients during clinical trials and 91.5 percent patients were found to be cured within seven days and their RT-PCR reports were negative.
The price of Virafin which is around 12 thousand rupees, which looks summarily expensive but if the claim made about the effect of the drug is found to be true, then the corona patient is currently going from hospitalization to expensive ones. It can also be said to be economical in comparison to the way it has been seen struggling with the shortage of injection and oxygen. Only time will tell how effective this medicine proves to be.